Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Endocrine therapy and endocrine resistant breast cancer

IMPAKT 2012

Published: 17 May 2012

Views: 4352

Rating:

Save

Prof Mitch Dowsett – The Institute for Cancer Research, London, UK

Prof Mitch Dowsett talks to ecancer about important papers presented at IMPAKT 2012 in Brussels, May 2012, on endocrine therapy, drug resistance, cell cycling and combination therapy.

Prof Dowsett discusses findings on everolimus, data from the BOLERO-2 study, which was presented by Prof Jose Baselga, and the outcomes from a phase 2 study involving CDK inhibitors.

Filming Supported by Amgen

Related Videos

Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer

Dr James Martin - Cleveland Clinic, Cleveland, USA

Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer ( Dr James Martin - Cleveland Clinic, Cleveland, USA )

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC

Dr Anna Wagner - The University of Lausanne, Lausanne, Switzerland, Co-chair of the EORTC Gastric Cancer Task Force

Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC ( Dr Anna Wagner - The University of Lausanne, Lausanne, Switzerland, Co-chair of the EORTC Gastric Cancer Task Force )

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer

Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City, USA

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer ( Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City, USA )

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )

IORT at the Asian Hospital and Medical Center

Dr Aldine Basa - Asian Hospital and Medical Center, Manila, Philippines

IORT at the Asian Hospital and Medical Center ( Dr Aldine Basa - Asian Hospital and Medical Center, Manila, Philippines )

Insights from TARGIT-A trial of targeted IORT during lumpectomy for breast cancer

Dr Jayant Vaidya - University College London, London, UK

Insights from TARGIT-A trial of targeted IORT during lumpectomy for breast cancer ( Dr Jayant Vaidya - University College London, London, UK )

Surgical management of Axilla: Past, present and future

Prof Terry Mamounas - Orlando Health Cancer Institute, Orlando, USA

Surgical management of Axilla: Past, present and future ( Prof Terry Mamounas - Orlando Health Cancer Institute, Orlando, USA )

Cancer pain management

Prof Ebtesam Ahmed - St John's University New York, New York City, USA

Cancer pain management ( Prof Ebtesam Ahmed - St John's University New York, New York City, USA )

More from ecancer